BL-M02D1
mAbexperimental
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started May 20, 2022 (NCT05339685)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- LymphocytesINHIBITOR
Lymphocytes inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05949619 | Phase 1/Phase 2 (Phase 2) | Sep 4, 2023 | Baili Pharmaceutical Group, Huazhong University of Science and Technology |
| NCT05385692 | Phase 1 | Jun 1, 2022 | Baili Pharmaceutical Group, Sun Yat-Sen University, SystImmune Inc. |
| NCT05339685 | Phase 1 | May 20, 2022 | Baili Pharmaceutical Group, Sun Yat-Sen University, SystImmune Inc. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Baili Pharmaceutical Group | For profit | 3 | 3 | 2 | 2022 |
| Sun Yat-Sen University | Academic/Hospital | 2 | 0 | 1 | 2022 |
| SystImmune Inc. | For profit | 2 | 0 | 1 | 2022 |
| Huazhong University of Science and Technology | Academic/Hospital | 1 | 0 | 1 | 2023 |
4 organizations
Page 1 / 1